e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Cystic fibrosis lung disease: what do we measure? What do we know?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dietary supplementation over one year with fatty acids reduces inflammatory markers and produces clinical improvement in adults with cystic fibrosis
F. Espildora, E. Acosta, G. Olveira, C. Olveira, E. Casado, A. Dorado (Malaga, Spain)
Source:
Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Session:
Cystic fibrosis lung disease: what do we measure? What do we know?
Session type:
Electronic Poster Discussion
Number:
344
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Espildora, E. Acosta, G. Olveira, C. Olveira, E. Casado, A. Dorado (Malaga, Spain). Dietary supplementation over one year with fatty acids reduces inflammatory markers and produces clinical improvement in adults with cystic fibrosis. Eur Respir J 2007; 30: Suppl. 51, 344
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Supplementation with polyunsaturated fatty acids influence the inflammatory response and airway nitric oxide in patients with cystic fibrosis
Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation
Year: 2008
Effects of n-3 polyunsaturated fatty acids on inflammatory markers in chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 39s
Year: 2006
Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth
Source: Eur Respir J 2015; 46: 1033-1045
Year: 2015
The role of free fatty acids in idiopathic pulmonary fibrosis
Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases
Year: 2017
The effect of conjugated linoleic acid supplementation on the nutritional status of COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Association between Ω3 and Ω6 fatty acid dietary intakes and serum inflammatory markers in Spanish COPD patients
Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases
Year: 2010
The effect of dietary fatty acids on inflammation in primary lung mesenchymal cells
Source: International Congress 2018 – COPD: immune regulation and therapeutic targets
Year: 2018
Plasma fatty acids and lipid hydroperoxides increase after antibiotic therapy in cystic fibrosis
Source: Eur Respir J 2007; 29: 958-964
Year: 2007
Is the unbalance between arachidonic acid and docosahexaenoic acid a reversible condition in adults With cystic fibrosis?
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
Effects of long-term supplementation of branched-chain amino acids on muscle metabolism in COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 638s
Year: 2006
Is adult asthma/chronic bronchitis related to the intake of fat especially polyunsaturated ω-6 and ω-3 fatty acids?
Source: Eur Respir J 2001; 18: Suppl. 33, 199s
Year: 2001
Oral polyunsaturated fatty acid supplementation as adjuvant therapy for asthmatic children
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Aging decreases reversibility of pulmonary fibrosis by regulating PRDM16-related fatty acid metabolism in lung fibroblasts
Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia
Year: 2021
Nutritional intervention in cystic fibrosis
Source: ISSN=1025-448x, ISBN=1-904097-27-8, page=153
Year: 2003
Glucocorticoids correct fatty acids composition in asthma patients. Composition of fatty acids in high density lipoproteins in bronchitis patients
Source: Eur Respir J 2007; 30: Suppl. 51, 145s
Year: 2007
Aging decreases pulmonary fibrosis reversibility via remodeling fatty acid metabolism of fibroblasts modulated by PRDM16
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
Nasal NO in cystic fibrosis is associated with CFTR genotype, pseudomonas colonization and fatty acids
Source: Eur Respir J 2005; 26: Suppl. 49, 404s
Year: 2005
Correlation between inflammatory and oxidation markers in adults with cystic fibrosis
Source: Annual Congress 2008 - Cystic fibrosis: a disease with many aspects
Year: 2008
The effect of dietary fatty acids on respiratory infection in human lung cells
Source: International Congress 2018 – Disease exacerbations from a molecular point of view
Year: 2018
Serum lipid concentrations and malnutrition in adult cystic fibrosis patients
Source: Eur Respir J 2006; 28: Suppl. 50, 58s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept